Identity and synonyms
Do not infer serotype, brand or potency from a catalog name.
Protein or biologic · Protein or protein analogue
Detailed molecular class: Protein/biologic; confirm exact product
Supplied sequence or chemical reference
Mechanism
Neurotoxin protein inhibiting acetylcholine release; product/type defines activity and units.
Evidence and critical reading
Reported scientific and empirical uses
Skin, hair and cosmetics
Specific products have authorized uses including spasticity, dystonias, chronic migraine and cosmetic indications depending on labeling.
Human evidence
OnabotulinumtoxinA evidence/authorization does not authenticate a vial sold as “botulinum toxin”. Units are not interchangeable between products.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
OnabotulinumtoxinA evidence/authorization does not authenticate a vial sold as “botulinum toxin”. Units are not interchangeable between products.
OnabotulinumtoxinA evidence/authorization does not authenticate a vial sold as “botulinum toxin”. Units are not interchangeable between products.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
US: BOTOX (onabotulinumtoxinA) has specific labeled indications. A generic supplier label does not identify that product, potency or approval.
Adverse effects and unknowns
Warning for toxin-effect spread, dysphagia and respiratory compromise. Aminoglycosides and drugs affecting neuromuscular transmission may potentiate effects per label.
Contraindications
BOTOX: hypersensitivity to toxin/components and infection at intended site; further contraindications depend on indication.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Aminoglycosides/agents interfering with neuromuscular transmission can potentiate effects; toxin units are not interchangeable.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
botulinum toxin · 1415 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07878780 · MRI Study of OnabotulinumtoxinA (OnabotA) Effect on Jaw Muscle PainRegistry status: Not yet recruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07875868 · Radial Extracorporeal Shock Wave Therapy as an Adjunct to Botulinum Toxin Type A for Post-Stroke Lower Limb Spasticity (SOLUTION)Registry status: CompletedLast update posted: October 15, 2026Query verification: October 16, 2026
NCT07874022 · Decision Regret Following Yonsei-Point Botulinum Toxin for Gummy SmileRegistry status: Not yet recruitingLast update posted: October 14, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- REG-BOTOX
DailyMed: BOTOX onabotulinumtoxinA
October 16, 2026
- SEARCH-PUBMED-botulinum-toxin
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026